BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38218752)

  • 1. Living with facioscapulohumeral muscular dystrophy during the first two COVID-19 outbreaks: a repeated patient survey in the Netherlands.
    Deenen JCW; Kools J; Greco A; Thewissen R; van de Put W; Lanser A; Joosten LAB; Verbeek ALM; van Engelen BGM; Voermans NC
    Acta Neurol Belg; 2024 Apr; 124(2):559-566. PubMed ID: 38218752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.
    Fitzgerald BP; Conn KM; Smith J; Walker A; Parkhill AL; Hilbert JE; Luebbe EA; Moxley RT
    J Neurol; 2016 Dec; 263(12):2528-2537. PubMed ID: 27734165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The French National Registry of patients with Facioscapulohumeral muscular dystrophy.
    Guien C; Blandin G; Lahaut P; Sanson B; Nehal K; Rabarimeriarijaona S; Bernard R; Lévy N; Sacconi S; Béroud C
    Orphanet J Rare Dis; 2018 Dec; 13(1):218. PubMed ID: 30514324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal and genitourinary symptoms in facioscapulohumeral muscular dystrophy: Prevalence and impact.
    Cole MR; Cooper CS; Hanna EM; Zimmerman MB; Kinoshita J; Mathews KD
    Muscle Nerve; 2024 Mar; 69(3):325-333. PubMed ID: 38158588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based incidence and prevalence of facioscapulohumeral dystrophy.
    Deenen JC; Arnts H; van der Maarel SM; Padberg GW; Verschuuren JJ; Bakker E; Weinreich SS; Verbeek AL; van Engelen BG
    Neurology; 2014 Sep; 83(12):1056-9. PubMed ID: 25122204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Perseverance of the Muscular Dystrophy Community One-Year into the COVID-19 Pandemic.
    Lewis L; Eichinger K; Dilek N; Higgs K; Walker M; Palmer D; Cooley JM; Johnson N; Tawil R; Statland J
    J Neuromuscul Dis; 2022; 9(4):517-523. PubMed ID: 35723112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facing facial weakness: psychosocial outcomes of facial weakness and reduced facial function in facioscapulohumeral muscular dystrophy.
    van de Geest-Buit WA; Rasing NB; Mul K; Deenen JCW; Vincenten SCC; Siemann I; Lanser A; Groothuis JT; van Engelen BG; Custers JAE; Voermans NC
    Disabil Rehabil; 2023 Jul; 45(15):2507-2516. PubMed ID: 35815498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dutch registry for facioscapulohumeral muscular dystrophy: Cohort profile and longitudinal patient reported outcomes.
    Kools J; Deenen JC; Blokhuis AM; Verbeek AL; Voermans NC; van Engelen BG
    Neuromuscul Disord; 2023 Dec; 33(12):964-971. PubMed ID: 38016873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry.
    Evangelista T; Wood L; Fernandez-Torron R; Williams M; Smith D; Lunt P; Hudson J; Norwood F; Orrell R; Willis T; Hilton-Jones D; Rafferty K; Guglieri M; Lochmüller H
    J Neurol; 2016 Jul; 263(7):1401-8. PubMed ID: 27159994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of functional impairment in Facioscapulohumeral muscular dystrophy.
    Statland JM; Tawil R
    Muscle Nerve; 2014 Apr; 49(4):520-7. PubMed ID: 23873337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-identified disease burden in facioscapulohumeral muscular dystrophy.
    Johnson NE; Quinn C; Eastwood E; Tawil R; Heatwole CR
    Muscle Nerve; 2012 Dec; 46(6):951-3. PubMed ID: 23225386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy.
    Jensen MP; Hoffman AJ; Stoelb BL; Abresch RT; Carter GT; McDonald CM
    Arch Phys Med Rehabil; 2008 Feb; 89(2):320-8. PubMed ID: 18226657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD).
    Goselink RJ; Schreuder TH; Mul K; Voermans NC; Pelsma M; de Groot IJ; van Alfen N; Franck B; Theelen T; Lemmers RJ; Mah JK; van der Maarel SM; van Engelen BG; Erasmus CE
    BMC Neurol; 2016 Aug; 16():138. PubMed ID: 27530735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facioscapulohumeral muscular dystrophy 1 patients participating in the UK FSHD registry can be subdivided into 4 patterns of self-reported symptoms.
    Banerji CRS; Cammish P; Evangelista T; Zammit PS; Straub V; Marini-Bettolo C
    Neuromuscul Disord; 2020 Apr; 30(4):315-328. PubMed ID: 32327287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ventilatory support in facioscapulohumeral muscular dystrophy.
    Wohlgemuth M; van der Kooi EL; van Kesteren RG; van der Maarel SM; Padberg GW
    Neurology; 2004 Jul; 63(1):176-8. PubMed ID: 15249635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The socioeconomic burden of facioscapulohumeral muscular dystrophy.
    Blokhuis AM; Deenen JCW; Voermans NC; van Engelen BGM; Kievit W; Groothuis JT
    J Neurol; 2021 Dec; 268(12):4778-4788. PubMed ID: 34043041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy.
    Goselink RJM; Mul K; van Kernebeek CR; Lemmers RJLF; van der Maarel SM; Schreuder THA; Erasmus CE; Padberg GW; Statland JM; Voermans NC; van Engelen BGM
    Neurology; 2019 Jan; 92(4):e378-e385. PubMed ID: 30568007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A patient-focused survey to assess the effects of the COVID-19 pandemic and social guidelines on people with muscular dystrophy.
    Eichinger K; Lewis L; Dilek N; Higgs K; Walker M; Palmer D; Cooley JM; Johnson N; Tawil R; Statland J
    Muscle Nerve; 2021 Sep; 64(3):321-327. PubMed ID: 34105174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for the management of facioscapulohumeral muscular dystrophy in 2011.
    Attarian S; Salort-Campana E; Nguyen K; Behin A; Andoni Urtizberea J
    Rev Neurol (Paris); 2012 Dec; 168(12):910-8. PubMed ID: 22551571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation.
    McNiff MM; Hawkins S; Haase B; Bullivant J; McIver T; Mitelman O; Emery N; Tasca G; Voermans N; Diaz-Manera J
    J Neuromuscul Dis; 2024; 11(2):459-472. PubMed ID: 38277300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.